法瓦瑞斯制药

最新新闻

• 评级变动
  Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $41
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $46 to $74
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• H.C. Wainwright Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $62
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  BofA Securities Maintains Pharvaris(PHVS.US) With Hold Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
  TipRanks · 2026/5/10
• 评级变动
  Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Raises Target Price to $46
  \u5e02\u573a\u8d44\u8baf · 2026/6/25
• 评级变动
  Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Cuts Target Price to $30.4
  \u5e02\u573a\u8d44\u8baf · 2026/5/18
• 评级变动
  A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $38 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $44 to $79
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  JonesTrading Maintains Pharvaris(PHVS.US) With Buy Rating, Raises Target Price to $52
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• Form 144(Amend) | Pharvaris(PHVS.US) Officer Proposes to Sell 7 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  JonesTrading Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $52
  \u5e02\u573a\u8d44\u8baf · 2026/8/29
• 评级变动
  Wedbush Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• Pharvaris (PHVS) Gets a Buy From H.C. Wainwright
  TipRanks · 2026/9/22
• 评级变动
  Oppenheimer Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• 评级变动
  BofA Securities Maintains Pharvaris(PHVS.US) With Hold Rating, Raises Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 3.5 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Wells Fargo Initiates Pharvaris(PHVS.US) With Buy Rating, Announces Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/9/8

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。